## Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

### ACHILLION PHARMACEUTICALS INC

Form 4

par value Common

11/20/2013

Stock,

\$0.001

par value

November 22, 2013

NOVCIIIOCI .	22, 2013											
FORM 4 UNITED STATES SECURITIES AND EVCHANCE COMMISSION									OMB APPROVAL			
Washington, D.C. 20549									OMB Number:	3235-0287		
if no lo	his box							Expires:	January 31, 2005			
subject Section Form 4	to <b>STATE</b> ! 16.	MENT OF CHANGES IN BENEFICIAL OWN SECURITIES						ERSHIP OF	Estimated a burden hou response	verage		
Form 5 obligati may co See Inst 1(b).	ons Section 17 truction	(a) of the	Public U	Jtility Ho		npany	Act of 1	Act of 1934, 1935 or Section	ı			
(Time of Type	(Responses)											
RA CAPITAL MANAGEMENT, Sy				2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
LLC	ACHILLION PHARMACEUTICALS INC					(Check all applicable)						
(Last)	(First)	(Middle)		Date of Earliest Transaction onth/Day/Year)				DirectorX 10% Owner Officer (give titleX Other (specify below)  See Footnotes (1)-(5)				
				0/2013								
			mendment, Date Original fonth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person					
BOSTON,	MA 02116						_	X_ Form filed by Merson	1 0			
(City)	(State)	(Zip)	Tal	ble I - Non	-Derivative S	Securi	ities Acqui	ired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transacti Code (Instr. 8)	4. Securitie or Disposed (Instr. 3, 4	d of (I	<b>)</b> )	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock, \$0.001	11/20/2013			P	250,000 (1)	A	\$ 2.6019	22,506,007	I	See Footnotes (4) (5)		

860,000

(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

P

(4) (5)

See

<u>(4)</u> <u>(5)</u>

Footnotes

23,366,007

I

\$ 2.53

## Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

SEC 1474 (9-02)

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title a Amount Underly Securitie (Instr. 3	of ing es	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title N	lumber		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships							
Troporting of their relation of the second	Director	10% Owner	Officer	Other				
RA CAPITAL MANAGEMENT, LLC 20 PARK PLAZA, SUITE 1200 BOSTON, MA 02116		X		See Footnotes (1)-(5)				
Kolchinsky Peter 20 PARK PLAZA, SUITE 1200 BOSTON, MA 02116		See Footnotes (1)-(5)						
RA Capital Healthcare Fund LP 20 PARK PLAZA, SUITE 1200 BOSTON, MA 02116		See Footnotes (1)-(5)						
Signatures								
/s/ Peter Kolchinsky, Manager of RA Ca		11/22/2013						
**Signature of Reporting Perso		Date						
/s/ Peter Kolchinsky, individually		11/22/2013						
**Signature of Reporting Perso		Date						
/s/ Peter Kolchinsky, General Partner of		11/22/2013						
**Signature of Reporting Perso		Date						

Reporting Owners 2

#### Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The securities purchased include 197,500 shares for RA Capital Healthcare Fund, L.P. (the "Fund") and 52,500 shares for an account owned by Blackwell Partners, LLC (the "Blackwell Account").
- (2) The securities purchased include 679,401 shares for RA Capital Healthcare Fund, L.P. (the "Fund") and 180,599 shares for an account owned by Blackwell Partners, LLC (the "Blackwell Account").
- (3) Following the transactions set forth on Table I above, 18,125,115 shares are held by the Fund, and 5,240,892 shares are held in the Blackwell Account.
- RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Blackwell Account.

  (4) Peter Kolchinsky is the sole manager of the Adviser. In their respective capacities, each of Mr. Kolchinsky and the Adviser may be deemed to beneficially own the reported securities.
- Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interests therein. The filing of this Form 4 shall not be construed as an admission that Mr. Kolchinsky or the Adviser is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of securities reported herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.